|
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck. |
|
|
Honoraria - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Codiak Biosciences (Inst); Inzen Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst); Scenic Biotech |
Consulting or Advisory Role - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Inzen Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Oncolys BioPharma (Inst); Replimune (Inst) |
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst) |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Replimune (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Blueprint Medicines; Macrogenics; Merck; Prelude Therapeutics |
Research Funding - Aduro Biotech (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Exelixis; Merck; Regeneron |
Research Funding - Alkermes (Inst); Genentech/Roche (Inst); Merck (Inst); Merck Serono (Inst); Merck Serono (Inst); Regeneron (Inst) |
|
|
Honoraria - Bristol-Myers Squibb/Pfizer; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology; Transgene |
Consulting or Advisory Role - Merck KGaA |
Research Funding - ALX Oncology (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Merck; MSD Oncology (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology |
Other Relationship - Merck; MSD Oncology |
|
|
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Merck KGaA; MSD; Nanobiotix; Roche; Seagan |
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Merck KGaA; MSD |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
|
Stock and Other Ownership Interests - Replimune |
Travel, Accommodations, Expenses - Replimune |